Tsuyoshi Yamamoto, Chisato Terada, Koki Kashiwada, Asako Yamayoshi, Mariko Harada-Shiba, Satoshi Obika
下载PDF
{"title":"Synthesis of Monovalent N-Acetylgalactosamine Phosphoramidite for Liver-Targeting Oligonucleotides","authors":"Tsuyoshi Yamamoto, Chisato Terada, Koki Kashiwada, Asako Yamayoshi, Mariko Harada-Shiba, Satoshi Obika","doi":"10.1002/cpnc.99","DOIUrl":null,"url":null,"abstract":"<p>Ligand-targeted drug delivery (LTDD) has emerged as an attractive option in the field of oligonucleotide drugs following the great success of <i>N</i>-acetylgalactosamine (GalNAc)–conjugated siRNA and antisense oligonucleotides. GalNAc is a well-known ligand of the asialoglycoprotein receptor (ASGPR), and is classified as a C-type lectin associated with the metabolism of desialylated glycoproteins. This article describes the synthesis of a non-nucleosidic monovalent GalNAc phosphoramidite—a useful reagent for facilitating the conjugation of GalNAc epitopes into oligonucleotides using DNA synthesizers—together with some important caveats. The monomeric GalNAc consists of three parts: (1) a GalNAc moiety, (2) a linker moiety, and (3) a <i>trans</i>-4-hydroxyprolinol (<i>t</i>HP) branch point. The GalNAc moiety and the <i>t</i>HP moiety are coupled via a condensation reaction to prepare the monovalent GalNAc phosphoramidite. © 2019 by John Wiley & Sons, Inc.</p><p><b>Basic Protocol 1</b>: Synthesis of <i>N</i>-acetylgalactosamine ligand</p><p><b>Basic Protocol 2</b>: Preparation of <i>trans</i>-4-hydroxyprolinol building block</p><p><b>Basic Protocol 3</b>: Preparation of GalNAc phosphoramidite</p>","PeriodicalId":10966,"journal":{"name":"Current Protocols in Nucleic Acid Chemistry","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2019-09-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1002/cpnc.99","citationCount":"4","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Protocols in Nucleic Acid Chemistry","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cpnc.99","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"Chemistry","Score":null,"Total":0}
引用次数: 4
引用
批量引用
Abstract
Ligand-targeted drug delivery (LTDD) has emerged as an attractive option in the field of oligonucleotide drugs following the great success of N -acetylgalactosamine (GalNAc)–conjugated siRNA and antisense oligonucleotides. GalNAc is a well-known ligand of the asialoglycoprotein receptor (ASGPR), and is classified as a C-type lectin associated with the metabolism of desialylated glycoproteins. This article describes the synthesis of a non-nucleosidic monovalent GalNAc phosphoramidite—a useful reagent for facilitating the conjugation of GalNAc epitopes into oligonucleotides using DNA synthesizers—together with some important caveats. The monomeric GalNAc consists of three parts: (1) a GalNAc moiety, (2) a linker moiety, and (3) a trans -4-hydroxyprolinol (t HP) branch point. The GalNAc moiety and the t HP moiety are coupled via a condensation reaction to prepare the monovalent GalNAc phosphoramidite. © 2019 by John Wiley & Sons, Inc.
Basic Protocol 1 : Synthesis of N -acetylgalactosamine ligand
Basic Protocol 2 : Preparation of trans -4-hydroxyprolinol building block
Basic Protocol 3 : Preparation of GalNAc phosphoramidite
肝靶向寡核苷酸单价N-乙酰氨基半乳糖的合成
在N-乙酰氨基半乳糖(GalNAc)偶联的siRNA和反义寡核苷酸取得巨大成功后,配体靶向药物递送(LTDD)已成为寡核苷酸药物领域的一个有吸引力的选择。GalNAc是去唾液酸糖蛋白受体(ASGPR)的一种众所周知的配体,被归类为一种与去分析糖蛋白代谢相关的C型凝集素。本文描述了一种非核苷单价GalNAc亚磷酸酰胺的合成,以及一些重要的注意事项。单体GalNAc由三部分组成:(1)GalNAc部分,(2)接头部分,和(3)反式-4-羟基脯氨酸(tHP)分支点。GalNAc部分和tHP部分通过缩合反应偶联以制备单价GalNAc磷酰胺。©2019 John Wiley&Sons,股份有限公司版权所有。
本文章由计算机程序翻译,如有差异,请以英文原文为准。